Remission rates in csDMARD-IR patients: at 3 and 6 months
| Tofacitinib 5 mg and 10 mg52 | DAS28(CRP): 18–22% | DAS28(CRP): 25–40% |
| SDAI: 4–7%, CDAI: 5–6% | SDAI: 7–15%, CDAI: 7–15% | |
| Boolean: 2–7% | Boolean: 6–12% | |
| Baricitinib 2 mg and 4 mg53 54 | DAS28(CRP): 19–26% | DAS28(CRP): 31–35% |
| SDAI: 8–9%, CDAI: 8–10% | SDAI: 15–17%, CDAI: 15–16% | |
| Boolean: 7% | Boolean: 12–13% | |
| Upadacitinib 15 mg55 | DAS28(CRP): 28–31% | DAS28(CRP): 39–41% |
| SDAI: 12–14%, CDAI: 13% | SDAI: 15–20%, CDAI: 13–21% | |
| Boolean: 7–10% | Boolean: 9–19% | |
| Filgotinib 100 mg and 200 mg56 57 | DAS28(CRP): 24% | DAS28(CRP): 35–48% |
| SDAI: 9–13%, CDAI: 11–12% | SDAI: 18–23%, CDAI: 19–21% | |
| Boolean: 7–10% | Boolean: 14–19% |
CDAI, Clinical Disease Activity Index; DAS28(CRP), Disease Activity Score28(CRP); SDAI, Simplified Disease Activity Index.